A human study of a topical gout pain product from Thousand Oaks-based Dyve Biosciences returned positive results, the company announced March 20. The results of the double-blind proof-of-concept pilot study were presented at a workshop at the European Crystal Network in Paris March 14-15. Dyve products aim to deliver known molecules like sodium bicarbonate –…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
